Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Sales Slide 7 Percent in Q1 as Charges Turn Profit to Loss

NEW YORK (GenomeWeb News) — Affymetrix today said first-quarter revenues dropped 7 percent as R&D spending fell 16 and a profit turned to a loss on restructuring charges.
 
Total receipts for the three months ended March 31 fell to $80.4 million from $86.4 million year over year.
 
Product and product-related revenue decreased 10 percent to $71.3 million; royalties and "other" revenue increased 33 percent to $2.4 million; and receipts from Perlegen rose 26 percent to $6.7 million.
 
R&D spending decreased to $19.7 million from $23.5 million.
 
The company said net loss was $4 million, down from a profit of $1.8 million in the year-ago period. Affy said the disparity was the result of $5.4 million in restructuring charges.
 
Affy said it had around $96.3 million in cash and equivalents and $146.9 million in short-term investments as of March 31.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more